1259020-79-5Relevant academic research and scientific papers
Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
Lee, Suk Ho,Kim, Min Ju,Lee, Sung-Han,Kim, Jeongmin,Park, Hyun-Ju,Lee, Jinhwa
, p. 2662 - 2675 (2011/07/08)
In order to investigate SAR regarding proximal phenyl ring in novel C-aryl glucoside SGLT2 inhibitors containing a thiazole motif, a series of chemical modifications on proximal phenyl ring was conducted. During a series of lead optimization efforts, orth
Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
Kim, Min Ju,Lee, Suk Ho,Park, So Ok,Kang, Hyunku,Lee, Jun Sung,Lee, Ki Nam,Jung, Myung Eun,Kim, Jeongmin,Lee, Jinhwa
, p. 5468 - 5479 (2011/10/30)
Novel macrocyclic C-aryl glucoside SGLT2 inhibitors were designed and synthesized. Two different synthetic routes of macrocyclization were adopted to prepare novel ansa SGLT2 inhibitors. Among the compounds tested, [1,7]dioxacyclopentadecine macrocycles p
THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
, (2012/01/06)
The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.
NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
-
Page/Page column 118, (2010/12/31)
A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.
